Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) - Drugs In Development, 2021

June 2021 | 95 pages | ID: N8567FA477DBEN
Global Markets Direct

Abstracts

Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) - Drugs In Development, 2021, provides an overview of the Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) pipeline landscape.

Nasal polyps (Nasal polyposis) is an inflammatory condition develops in the nasal lining of nose. They are non-cancerous growths. Signs and symptoms include runny nose, postnasal drip, headache, snoring and loss of sense of taste. Risk factors include asthma, aspirin sensitivity, cystic fibrosis, Churg-strauss syndrome and allergic fungal sinusitis. Treatment includes steroid medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Nasal Polyps (Nasal Polyposis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 3, 1 and 1 respectively.

Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders).
• The pipeline guide reviews pipeline therapeutics for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Nasal Polyps (Nasal Polyposis) - Overview
Nasal Polyps (Nasal Polyposis) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Nasal Polyps (Nasal Polyposis) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Nasal Polyps (Nasal Polyposis) - Companies Involved in Therapeutics Development
AnaptysBio Inc
ConMed Biosciences Inc
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Kyowa Kirin Co Ltd
Novartis AG
OptiNose Inc
Pfizer Inc
Suzhou Connect Biopharmaceuticals Ltd
Nasal Polyps (Nasal Polyposis) - Drug Profiles
benralizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBP-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-310 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etokimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fevipiprant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fluticasone propionate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mepolizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omalizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06817024 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nasal Polyps (Nasal Polyposis) - Dormant Projects
Nasal Polyps (Nasal Polyposis) - Discontinued Products
Nasal Polyps (Nasal Polyposis) - Product Development Milestones
Featured News & Press Releases
Apr 12, 2021: Novartis receives FDA approval of Xolair (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients
Dec 08, 2020: FDA accepts GSK’s filing of Nucala (mepolizumab) for use in chronic rhinosinusitis with nasal polyps
Dec 01, 2020: Genentech announces FDA approval of Xolair (omalizumab) for adults with nasal polyps
Oct 29, 2020: GSK Nucala (mepolizumab) filings accepted by European Medicines Agency for three additional eosinophil-driven diseases
Sep 10, 2020: AstraZeneca reports positive results from OSTRO trial of Fasenra
Aug 10, 2020: AnaptysBio reports top-line data from interim analysis of ECLIPSE phase 2 clinical trial of Etokimab in chronic rhinosinusitis with nasal polyps
Aug 06, 2020: Novartis receives EC approval for new Xolair indication to treat severe chronic rhinosinusitis with nasal polyps
Jul 08, 2020: Optinose announces XHANCE co-promotion agreement with Kal?o
Jun 26, 2020: Novartis receives positive CHMP opinion for new Xolair indication to treat severe chronic rhinosinusitis with nasal polyps
Apr 03, 2020: Nucala (mepolizumab) is the first anti-IL5 biologic to report positive phase 3 results in patients with nasal polyps
Dec 17, 2019: Optinose announces peer-reviewed publication of the fourth major XHANCE registration trial
Dec 11, 2019: FDA agrees to review Novartis’ sBLA of Xolair to treat nasal polyps
Sep 12, 2019: Optinose announces $150 million debt financing from Pharmakon
Jun 03, 2019: Xolair (Omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies
Feb 19, 2019: Optinose announces issuance of four additional U.S. patents covering XHANCE
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Nasal Polyps (Nasal Polyposis), 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Nasal Polyps (Nasal Polyposis) - Pipeline by AnaptysBio Inc, 2021
Nasal Polyps (Nasal Polyposis) - Pipeline by ConMed Biosciences Inc, 2021
Nasal Polyps (Nasal Polyposis) - Pipeline by F. Hoffmann-La Roche Ltd, 2021
Nasal Polyps (Nasal Polyposis) - Pipeline by GlaxoSmithKline Plc, 2021
Nasal Polyps (Nasal Polyposis) - Pipeline by Kyowa Kirin Co Ltd, 2021
Nasal Polyps (Nasal Polyposis) - Pipeline by Novartis AG, 2021
Nasal Polyps (Nasal Polyposis) - Pipeline by OptiNose Inc, 2021
Nasal Polyps (Nasal Polyposis) - Pipeline by Pfizer Inc, 2021
Nasal Polyps (Nasal Polyposis) - Pipeline by Suzhou Connect Biopharmaceuticals Ltd, 2021
Nasal Polyps (Nasal Polyposis) - Dormant Projects, 2021
Nasal Polyps (Nasal Polyposis) - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Nasal Polyps (Nasal Polyposis), 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021